How to Buy Accolade Stock
Accolade Inc
Accolade, Inc. , together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.
Accolade stock last closed at $7.08, down 1.12% from the previous day, and has decreased 41.2% in one year. It has underperformed other stocks in the Health Information Services industry by 0.16 percentage points. Accolade stock is currently +11.85% from its 52-week low of $6.33, and -53.91% from its 52-week high of $15.36.
As of May 31, 2024, there are 78.36M ACCD shares outstanding. The market capitalization of ACCD is $554.77M. In the last 24 hours, 553,689 ACCD shares were traded.
How to Buy Accolade Stock
Wondering how to invest in Accolade stock? Here's how.
- Figure out where to buy Accolade stock: You need to choose an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Accolade stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your brokerage account: Select your method of payment and add your information.
- Evaluate Accolade stock: The Accolade ticker symbol is ACCD. Is Accolade stock a good investment? Should you buy shares of ACCD? How do ACCD's underlying business fundamentals look? Do top analysts think Accolade is a good buy? Why has ACCD's stock price moved recently? (Hint: Our stock analysis website can help you understand if ACCD is a good stock to buy).
- Place your ACCD trade: Decide if you will purchase ACCD shares at the current market price or use a limit order to buy ACCD stock at a particular price.
- Get key alerts regarding your investment in ACCD: Create a watchlist to keep track of your new investment in Accolade shares.
Step 1: Figure out where to buy Accolade stock
You will need an online brokerage account in order to access the NASDAQ market and buy ACCD shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Energy, New York to London — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the best brokerage, you'll need to fill out some personal details so you are able to buy ACCD today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start a new trading account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on apps for stocks, you can securely and quickly fund your account:
Watch the video below if you need help depositing funds into your new investment account.
Step 4: Evaluate Accolade stock
Once you have chosen the best place to buy Accolade stock, it's crucial to evaluate their stock before you invest, so you actually comprehend the risk and opportunity.
Accolade Metrics
Fundamentals of Accolade
WallStreetZen was built to help average investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on ACCD's stock page.
What is the fair value of ACCD stock?
You can use a variety of different financial metrics, analyses, models, and charts to gauge ACCD's fair value.
Using relative valuations ratios:
- ACCD may be undervalued based on its P/B ratio of 1.25x, relative to Health Information Services industry P/B ratio of 3.11x
You can access more valuation analysis on ACCD's stock here.
A look at ACCD Cashflows and Balance Sheet
Pros:
- There are more short-term assets than short-term liabilities on the ACCD balance sheet.
- There are more short-term assets than long-term liabilities on the ACCD balance sheet.
- ACCD has cash burn of 28651000. It has sufficient cash and short-term investments to cover this for at least one year.
- ACCD has $237.03M in cash and short term investments. This is enough to cover its annual cash burn of $28.65M.
- Total ACCD debt is lower than 5 years ago, relative to shareholder equity.
- ACCD profit margin has gone up from -126.6% to -24.1% in the past year.
Cons:
- ACCD has a relatively high debt to equity ratio of 0.77.
Is it a good time to buy Accolade stock, according to analysts?
Out of 10 Equities analysts who give ratings on ACCD, the consensus analyst rating on ACCD is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Most Recent ACCD Analyst Forecasts
An analyst from Barclays maintains ACCD with a hold rating and lowers their ACCD price target from $13.00 to $11.00, on Apr 26, 2024.
David Grossman, a top 23% analyst from Stifel Nicolaus maintains ACCD with a strong buy rating and lowers their ACCD price target from $15.00 to $13.00, on Apr 22, 2024.
Michael Cherny, a bottom 10% analyst from Leerink Partners initiates coverage on ACCD with a buy rating and announces their ACCD price target of $16.00, on Feb 26, 2024.
Ryan MacDonald, a bottom 2% analyst from Needham reiterates ACCD with a buy rating and maintains their ACCD price target from $17.00 to $17.00, on Jan 19, 2024.
Jessica Tassan, a top 41% analyst from Piper Sandler maintains ACCD with a strong buy rating and raises their ACCD price target from $12.00 to $15.00, on Jan 9, 2024.
Piper Sandler's Jessica Tassan raised their price target on Accolade (NASDAQ: ACCD) by 25% from $12 to $15 on 2024/01/09. The analyst maintained their Strong Buy rating on the stock.
FY 2024 guidance moved slightly higher thanks to beats on revenue and adjusted EBITDA, the analyst reported in a note assessing Accolade's Q3 2024 report, released on 2024/01/08.
Accolade's Q3 outperformance will "level the Q4 ramp," ensuring that the company's revised FY 2024 guidance remains "entirely achievable," Tassan argued.
Citing an active pipeline, increasing intra-account activity, and technology-led efficiency gains, management expressed confidence in durable double-digit growth and raised FY 2029 margin targets [to 15% to 20% of revenue], the analyst reported.
Earnings Report
For Q3 2024, Accolade reported:
- Loss per share of $0.28, which beat the Zacks Consensus Estimate of ($0.46) and, by 50%, Q3 2023’s ($0.56).
- Revenue of $99.4M, which beat the Zacks Consensus Estimate of $96.5M and, by 9.4%, Q3 2023’s $90.9M.
- Adjusted EBITDA of ($4.6M), which beat Q3 2023’s ($10.2M) by 55%.
Management guided:
For Q4 2024:
- Revenue of $121.5M to $125.5M.
- Adjusted EBITDA of $16M to $20M.
For FY 2024:
- Revenue of $411M to $415M.
- Adjusted EBITDA of ($10M) to ($6M).
For FY 2025:
- Revenue growth of 20%.
- Adjusted EBITDA of 2% to 4% of revenue.
For FY 2029:
- Revenue of more than $1B.
- Adjusted EBITDA of 15% to 20% of revenue.
Chairman & CEO Rajeev Singh commented: “As we head into the new year, Accolade continues to define the future of how healthcare should be experienced in this country.
“Our unique combination of people and technology is creating a new model for improving health outcomes and helping our more than 10M members live healthier lives.
“We are closing the physician gap, improving access to care, and leveraging AI and other innovations to make the system work better for our employer customers, their employees and their families.
“The results can be seen in our growing customer base and increasing revenues as we plan to deliver positive adjusted EBITDA in Q4 and FY 2025.”
You can dive deeper into what analysts are projecting on the Accolade stock forecast page.
Metrics for Advanced ACCD Traders
How is ACCD performing as a company?
Last year, ACCD revenue was $414.29M. In the past five year, ACCD's revenue has grown by 34.3% per year. This was faster than the Health Information Services industry average of 20.71%.
You can research ACCD's earnings and revenue performance here.
Who is buying/selling ACCD?
Over the last year, executives and large shareholders at ACCD have bought more shares than they have sold.
Stephen H. Barnes, Chief Financial Officer of ACCD, was the latest ACCD insider to buy. They bought $12,922.87 worth of ACCD stock on May 22, 2024.
Learn more about who owns ACCD shares here.
Does ACCD provide a stable income stream?
No, Accolade doesn't provide an income stream by paying out dividends.
What do other traders have to say about ACCD?
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Place your ACCD trade
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact price, place a limit order.
Press the Open button and eToro will execute the order.
If you require additional help with buying stocks on eToro, watch the helpful video below:
Step 6: Get key alerts regarding your investment in ACCD
Now that you own some ACCD shares, you'll want to stay up-to-date on your shares.
Add ACCD to a watchlist to get alerted to the latest events about your ACCD stock.
ACCD Feed
How to Buy Stock in Accolade
To reiterate, here are the 6 steps to buy stock in Accolade:
- Figure out where to buy Accolade stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Evaluate Accolade stock
- Place your ACCD trade
- Get key alerts regarding your investment in ACCD
If you require a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to watch your investment in Accolade, hit the button below to create your watchlist.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.